Results from phase I dose escalation of IMC-F106C, the first PRAME X CD3 ImmTAC bispecific protein in solid tumors

Publication

Results from phase I dose escalation of IMC-F106C, the first PRAME X CD3 ImmTAC bispecific protein in solid tumors

Hamid, O.
;
Sato, T.
;
Davar, D.
;
Callahan, M. K.
;
Thistlethwaite, Fiona C
;
Aljumaily, R.
;
Johnson, M. L.
;
Arkenau, H. T.
;
Dumbrava, E. E. I.
;
Izar, B.
... show 9 more

Authors

Hamid, O.
Sato, T.
Davar, D.
Callahan, M. K.
Thistlethwaite, Fiona C
Aljumaily, R.
Johnson, M. L.
Arkenau, H. T.
Dumbrava, E. E. I.
Izar, B.
Chen, H. A.
Marshall, S.
Yuan, Y.
Deo, M.
Stanhope, S.
Collins, L.
Mundy, R.
Abdullah, S. E.
Lopez, J. S.

Affiliation

The Angeles Clinic And Research Institute, A Cedars Sinai Affiliate, 90025

Date

2022

Collections

All Christie Publications

Show all metadata

Type

Meetings and Proceedings

Citation

Hamid O, Sato T, Davar D, Callahan MK, Thistlethwaite F, Aljumaily R, et al. Results from phase I dose escalation of IMC-F106C, the first PRAME X CD3 ImmTAC bispecific protein in solid tumors. Annals of Oncology. 2022 Sep;33(7):S875-S. PubMed PMID: WOS:000866211600716.

URI

http://hdl.handle.net/10541/625962